Search results
Added:
1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study…
View more
Added:
7 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Added:
1 year ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR…
View more
Added:
1 month ago
Source:
Interventional Cardiology
Mirjam Boros, Radcliffe CardiologyDe-escalation of dual antiplatelet therapy (DAPT) is a strategy used to improve outcomes after percutaneous coronary intervention (PCI).¹˒² However, the impact of patient sex on the safety and efficacy of these strategies has been unclear. A new network meta-analysis published in the European Heart Journal has investigated these potential differences…
View more
Added:
1 year ago
Added:
1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel…
View more
Added:
2 years ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT…
View more
Added:
9 months ago
Added:
3 months ago
Source:
Radcliffe CVRM
Written by Mirjam Boros, Radcliffe CardiologyThe optimal dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in high-risk patients with diabetes and multivessel disease remains a key clinical question. The TUXEDO-2 trial aimed to address this by directly comparing the efficacy and safety of ticagrelor versus prasugrel in this specific patient population…
View more
Added:
2 months ago